Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

Simple item page
dc.contributor.authorBrunetti, Vanessa C.
dc.contributor.authorSt-Jean, Audray
dc.contributor.authorDell’Aniello, Sophie
dc.contributor.authorFisher, Anat
dc.contributor.authorYu, Oriana H. Y.
dc.contributor.authorBugden, Shawn C.
dc.contributor.authorDaigle, Jean-Marc
dc.contributor.authorHu, Nianping
dc.contributor.authorAlessi-Severini, Silvia
dc.contributor.authorShah, Baiju R.
dc.contributor.authorRonksley, Paul E.
dc.contributor.authorLix, Lisa M.
dc.contributor.authorErnst, Pierre
dc.contributor.authorFilion, Kristian B.
dc.date.accessioned2022-10-01T03:32:33Z
dc.date.issued2022-09-29
dc.date.updated2022-10-01T03:32:33Z
dc.description.abstractAbstract Background Characteristics of patients using newer 2nd and 3rd line antidiabetic drugs in a real-world setting are poorly understood. We described the characteristics of new users of sodium-glucose co-transporter-2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in Canada and the United Kingdom (UK) between 2016 and 2018. Methods We conducted a multi-database cohort study using administrative health databases from 7 Canadian provinces and the UK Clinical Practice Research Datalink. We assembled a base cohort of antidiabetic drug users between 2006 and 2018, from which we constructed 3 cohorts of new users of SGLT-2i, DPP-4i, and GLP-1 RA between 2016 and 2018. Results Our cohorts included 194,070 new users of DPP-4i, 166,722 new users of SGLT-2i, and 27,719 new users of GLP-1 RA. New users of GLP-1 RA were more likely to be younger (mean ± SD: 56.7 ± 12.2 years) than new users of DPP-4i (67.8 ± 12.3 years) or SGLT-2i (64.4 ± 11.1 years). In Canada, new users of DPP-4i were more likely to have a history of coronary artery disease (22%) than new users of SGLT-2i (20%) or GLP-1 RA (15%). Conclusion Although SGLT-2i, DPP-4i, and GLP-1 RAs are recommended as 2nd or 3rd line therapy for type 2 diabetes, important differences exist in the characteristics of users of these drugs. Contrary to existing guidelines, new users of DPP-4i had a higher prevalence of cardiovascular disease at baseline than new users of SGLT2i or GLP-1RA.
dc.identifier.citationBMC Endocrine Disorders. 2022 Sep 29;22(1):241
dc.identifier.urihttps://doi.org/10.1186/s12902-022-01140-1
dc.identifier.urihttp://hdl.handle.net/1993/36931
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderThe Author(s)
dc.titleCharacteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom
dc.typeJournal Article
local.author.affiliationRady Faculty of Health Sciencesen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12902_2022_Article_1140.pdf
Size:
931.11 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works